Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | USP7 |
| Gene Name: | USP7 |
| Protein Full Name: | Ubiquitin carboxyl-terminal hydrolase 7 |
| Alias: | Ubiquitin thioesterase 7 |
| Mass (Da): | 128302 |
| Number AA: | 1102 |
| UniProt ID: | Q93009 |
| Locus ID: | 7874 |
| COSMIC ID: | USP7 |
| Gene location on chromosome: | 16p13.3 |
| Cancer protein type: | OP/TSP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | MIXED |
| Number of cancer specimens: | 20149 |
| Percent of cancer specimens with mutations: | 0.95 |
| Normal role description: | USP7 interacts with the Epstein-Barr nuclear antigen 1 (EBNA1) protein of the Epstein-Barr virus, which is responsible for EBV latent infection and cellular transformation, and may thus play a role in EBV-mediated immortalization. It was first identified as a novel p53-interacting protein. It binds and stabilizes p53 through de-ubiquitination, and also strongly interacts with MDM2, therefore playing an important role in the p53-MDM2 pathway resulting in p53-dependent cell growth repression and apoptosis, and may hence function as a tumour suppressor. However, USP7 overexpression has been linked to prostate, bladder, colon, liver, and lung cancers, and inhibitors of USP7 such as P005091 have shown anti-proliferative activity in cancer models, indicating it is an oncoprotein in those tissues |
| Commentary on involvement of protein in cancer: | 1/46 CNS tumour samples was also mutated (Sanger COSMIC) |